A trial fibrillation (AF) is a frequent complication of longstanding hypertension and represents the most common cardiac arrhythmia causing significant morbidity and mortality.1-3 During AF, normal atrioventricular (AV) node conduction leads to a rapid and irregular ventricular rate, resulting in an impairment of left ventricular function and exercise capacity. 4 Rate control can be achieved by drugs modulating the autonomic nervous system, for example, by β-blockers. Genetic inhibition of inhibitory Gα protein in the AV node reduced heart rate (HR) and prevented AF-associated reduction of cardiac function in a porcine model for persistent AF.
5In addition, AF causes atrial electrical remodeling mainly characterized by a pronounced atrial effective refractory period (AERP) shortening perpetuating AF.6 Alterations in the autonomic nervous system may influence AF-induced atrial electrical remodeling and atrial arrhythmogenesis.7-9 Catheterbased renal denervation (RDN) is a new therapeutic approach to reduce sympathetic activity and blood pressure (BP) and to improve obstructive sleep apnea severity and glucose metabolism in resistant hypertension. [10][11][12][13][14][15] However, the effect of RDN on ventricular HR response during AF (rate control) and AF-induced electrical remodeling is unknown.Herein, we report on the effect of catheter-based RDN, shown previously to reduce renal and whole body sympathetic activity, 12-14 on rate control in a patient with permanent AF and resistant hypertension. Subsequently, we investigated the effect of denervation of the afferent and efferent renal sympathetic nerves in a pig model with short-term AF maintained by rapid atrial pacing.
Methods
Catheter-Based RDN in a Patient With AFThe patient gave written informed consent. Catheter-based RDN was performed as described previously.11-15 Renal angiogram was performed via femoral access to exclude renal artery stenosis. The treatment catheter (Symplicity Catheter System, Ardian/Medtronic USA) Abstract-Renal denervation (RDN) reduces renal efferent and afferent sympathetic activity thereby lowering blood pressure in resistant hypertension. The effect of modulation of the autonomic nervous system by RDN on atrial electrophysiology and ventricular rate control during atrial fibrillation (AF) is unknown. Here we report a reduction of ventricular heart rate in a patient with permanent AF undergoing RDN. Subsequently, we investigated the effect of RDN on AF-induced shortening of atrial effective refractory period, AF inducibility, and ventricular rate control during AF maintained by rapid atrial pacing in 12 pigs undergoing RDN (n=7) or sham procedure (n=5